| HOME >> BIOLOGY >> TECHNOLOGY |
Cautionary Note Concerning Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of applicable securities laws in the United States and Canada.
Forward-looking statements involve risks and uncertainties, including risks
and uncertainties related to compliance by either Biomira or Oncothyreon
with applicable Nasdaq listing requirements; the impact of the proposed
effective reverse stock split on compliance with Nasdaq listing
requirements; benefits currently anticipated to be derived from the
proposed reincorporation transaction; and Biomira's business, including,
without limitation, statements related to our agreements with Merck KGaA,
the therapeutic and commercial potential of Stimuvax and other drug
candidates in our clinical development pipeline, benefits anticipated from
the acquisition of ProlX, future clinical development plans, the details of
our planned clinical trials, the regulatory approval process and the
general economic environment. A number of factors could cause actual
results or events to differ materially from those anticipated by
forward-looking statements. In particular, neither Biomira nor Oncothyreon
can predict whether the conditions to completion of the reincorporation,
including shareholder and judicial approvals, will be obtained. In
addition, even if the reincorporation and the associated effective reverse
stock split are approved and implemented, neither Biomira nor Oncothyreon
can provide any assurances that they will continue to satisfy Nasdaq
listing requirements. The business of Biomira and, assuming completion of
the arrangement, the business of Oncothyreon are subject to numerous risks
and uncertainties associated with biopharmaceutical development companies,
including risks relating to the results of clin
'/>"/>
| SOURCE Biomira Inc. Copyright©2007 PR Newswire. All rights reserved |